Is the determination of biomarkers worth its price? Review of the literature taking brain natriuretic peptides (BNP) as an example;Sind Biomarker ihr Geld wert?: Literaturreview am Beispiel B-natriuretischer Peptide (BNP)

Herz

Volumn 35, Issue 1, 2010, Pages 1-10

  Reinhold, Thomas ^a   Berghöfer, Anne ^a   Willich, Stefan N ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Brain natriuretic peptide; Cost effectiveness; Costs; Health economy

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE;

COST EFFECTIVENESS ANALYSIS; FINANCE; GERMANY; HEALTH CARE SYSTEM; HEART FAILURE; HUMAN; PROGNOSIS; PUBLIC HEALTH SERVICE; REVIEW; SCREENING;

BIOLOGICAL MARKERS; COST-BENEFIT ANALYSIS; ECHOCARDIOGRAPHY; HEART FAILURE; HUMANS; NATIONAL HEALTH PROGRAMS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 76749113390     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-010-3312-8     Document Type: Review

References (27)

1. W.B. Kannel 2000 Incidence and epidemiology of heart failure Heart Fail Rev 5 167 73 10.1023/A:1009884820941 1:STN:280:DC%2BD2MrltVeluw%3D%3D 16228142 (Pubitemid 30675947)
2. M.R. Cowie A. Mosterd D.A. Wood 1997 The epidemiology of heart failure Eur Heart J 18 208 25 1:CAS:528:DyaK2sXht1ymtrs%3D 9043837
3. A. Mosterd A.W. Hoes M.C. de Bruyne 1999 Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study Eur Heart J 20 447 55 10.1053/euhj.1998.1239 1:STN:280:DyaK1M3ivVelsA%3D%3D 10213348 (Pubitemid 29116541)
4. F. Breyer S. Felder 2006 Life expectancy and health care expenditures: a new calculation for Germany using the costs of dying Health Policy 75 178 86 10.1016/j.healthpol.2005.03.011 15893848 (Pubitemid 41772549)
5. S. Gielen M. Sandri GC. [. Schuler 2006 Acute heart failure: rational diagnostics in clinical practice and the emergency department Herz 31 736 47 10.1007/s00059-006-2916-5 17149675 (Pubitemid 44940005)
6. S.N. Willich T. Reinhold C. Lenz 2005 Herzinsuffizienz nach Myokardinfarkt in Deutschland - ökonomische Bedeutung und Einschränkung der Lebensqualität Pharmacoeconomics German Res Art 3 25 39
7. Krankheitskosten in Mio. € für Deutschland. Gliederungsmerkmale: Jahre, Alter, Geschlecht, ICD10. 2009 (verfügbar unter http://www.gbe-bund.de, Zugriff am 31.07.2009).
8. Diagnosedaten der Krankenhäuser ab 2000 (Eckdaten der vollstationären Patienten und Patientinnen). Gliederungsmerkmale: Jahre, Region, ICD10. 2007 (verfügbar unter http://www.gbe-bund.de, Zugriff am 31.07.2009).
9. Häufigste Diagnosen in Prozent der Behandlungsfälle in Arztpraxen in Nordrhein (Rang und Anteil). Gliederungsmerkmale: Jahre, Nordrhein, Geschlecht, ICD10, Arztgruppe. 2007 (verfügbar unter http://www.gbe-bund.de, Zugriff am 31.07.2009).
10. Q. Dao P. Krishnaswamy R. Kazanegra 2001 Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting J Am Coll Cardiol 37 379 85 10.1016/S0735-1097(00)01156-6 1:CAS:528: DC%2BD3MXhsl2jt7Y%3D 11216950
11. P.A. Heidenreich M.A. Gubens G.C. Fonarow 2004 Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction J Am Coll Cardiol 43 1019 26 10.1016/j.jacc.2003. 10.043 1:CAS:528:DC%2BD2cXkt12isbY%3D 15028361 (Pubitemid 38352983)
12. D. Tepper 2001 Frontiers in congestive heart failure: utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent care setting Congest Heart Fail 7 330 11828181
13. K. Dickstein A. Cohen-Solal G. Filippatos 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J 29 2388 442 10.1093/eurheartj/ehn309 1:CAS:528:DC%2BD1cXhtlGisbvO 18799522
14. C.E. Angermann G. [. Ertl 2004 Natriuretic peptides - new diagnostic markers in heart disease Herz 29 609 17 10.1007/s00059-004-2619-8 15912436 (Pubitemid 39366051)
15. C. Mueller A. Scholer K. Laule-Kilian 2004 Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea N Engl J Med 350 647 54 10.1056/NEJMoa031681 1:CAS:528:DC%2BD2cXhtFCrtro%3D 14960741 (Pubitemid 38364623)
16. C. Mueller K. Laule-Kilian C. Schindler 2006 Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea Arch Intern Med 166 1081 7 10.1001/archinte.166.10.1081 16717170 (Pubitemid 43765179)
17. T. Breidthardt K. Laule A.H. Strohmeyer 2007 Medical and economic long-term effects of B-type natriuretic peptide testing in patients with acute dyspnea Clin Chem 53 1415 22 10.1373/clinchem.2006.081448 1:CAS:528: DC%2BD2sXosVKqs7s%3D 17586596 (Pubitemid 47206337)
18. J.H. Rutten E.W. Steyerberg F. Boomsma 2008 N-terminal pro-brain natriuretic peptide testing in the emergency department: beneficial effects on hospitalization, costs, and outcome Am Heart J 156 71 7 10.1016/j.ahj.2008.02. 021 1:CAS:528:DC%2BD1cXnvVGks7s%3D 18585499
19. U. Siebert J.L. Januzzi Jr M.T. Beinfeld 2006 Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department Am J Cardiol 98 800 5 10.1016/j.amjcard.2006.06.005 1:CAS:528:DC%2BD28Xptlyrs70%3D 16950189 (Pubitemid 44301027)
20. R. Valle N. Aspromonte E. Carbonieri 2008 Fall in readmission rate for heart failure after implementation of B-type natriuretic peptide testing for discharge decision: a retrospective study Int J Cardiol 126 400 6 10.1016/j.ijcard.2006.03.097 17804095 (Pubitemid 351636361)
21. O.W. Nielsen T.A. McDonagh S.D. Robb 2003 Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population J Am Coll Cardiol 41 113 20 10.1016/S0735-1097(02)02625-6 12570953 (Pubitemid 36044412)
22. K.M. Goode A.L. Clark J.G. Cleland 2008 Ruling out heart failure in primary-care: the cost-benefit of pre-screening using NT-proBNP and QRS width Int J Cardiol 130 426 37 10.1016/j.ijcard.2007.08.131 18178273
23. H. Dokainish W.A. Zoghbi E. Ambriz 2006 Comparative cost-effectiveness of B-type natriuretic peptide and echocardiography for predicting outcome in patients with congestive heart failure Am J Cardiol 97 400 3 10.1016/j.amjcard.2005.08.060 16442404 (Pubitemid 43133058)
24. T.K. Lim G. Dwivedi S. Hayat 2007 Cost effectiveness of the B type natriuretic peptide, electrocardiography, and portable echocardiography for the assessment of patients from the community with suspected heart failure Echocardiography 24 228 36 10.1111/j.1540-8175.2007.00398.x 17313633 (Pubitemid 46280596)
25. T. Morimoto Y. Hayashino T. Shimbo 2004 Is B-type natriuretic peptide-guided heart failure management cost-effective? Int J Cardiol 96 177 81 10.1016/j.ijcard.2003.05.036 15262031 (Pubitemid 38979896)
26. V. Sim D. Hampton C. Phillips 2003 The use of brain natriuretic peptide as a screening test for left ventricular systolic dysfunction - cost-effectiveness in relation to open access echocardiography Fam Pract 20 570 4 10.1093/fampra/cmg513 14507800 (Pubitemid 37258762)
27. A. Manca A.R. Willan 2006 "Lost in translation": accounting for between-country differences in the analysis of multinational cost-effectiveness data Pharmacoeconomics 24 1101 19 10.2165/00019053-200624110-00007 17067195